Chapter 12: Introduction to Psychotropic Drugs

Introduction to Psychotropic Drugs begins by tracing the historical evolution of psychotropic drugs, from the serendipitous discoveries of lithium and chlorpromazine to modern atypical antipsychotics and SSRIs, highlighting how these agents have enabled less restrictive care environments. A significant portion of the text is dedicated to pharmacokinetics, detailing how the body processes drugs through absorption, distribution, metabolism, and excretion. Key concepts include bioavailability, the impact of first-pass metabolism in the liver, and the nuances of protein binding which determines the availability of free drug molecules. The chapter provides an in-depth analysis of the blood-brain barrier, explaining how anatomic, physiologic, and metabolic dimensions—specifically lipid solubility and the P-glycoprotein efflux transporter system—regulate the entry of substances into the central nervous system. Metabolism is explored through the lens of the cytochrome P-450 (CYP-450) enzyme system and the monoamine oxidase (MAO) system, with specific attention given to how factors like smoking (enzyme induction) and genetic variations (poor versus ultrarapid metabolizers) alter drug efficacy and toxicity risks. The discussion on pharmacodynamics examines how drugs affect the body, defining mechanisms such as receptor agonism and antagonism, down-regulation, and pharmacodynamic tolerance. Furthermore, the text elucidates the neurobiological basis of drug action, describing the structure of neurons and synapses, and the specific functions of major neurotransmitters including dopamine, norepinephrine, serotonin, acetylcholine, GABA, and glutamate. It explains how dysregulation in these chemical messengers correlates with disorders like schizophrenia, depression, and anxiety. The chapter concludes by outlining essential nursing responsibilities, such as monitoring for side effects and drug-drug interactions, and underscores the importance of patient education regarding adherence, safety, and lifestyle factors to optimize therapeutic outcomes across the lifespan.